2025 · Schizophrenia research. Cognition · open access
Migration of digital functional capacity assessments from device resident to cloud-based delivery: Development and convergent validity
Harvey et al.
The finding, in our words
Healthy older adults performed similarly on functional capacity tests whether delivered by computer or cloud-based tablet, with only a five per cent speed improvement on the iPad version of one test. This supports the feasibility of migrating digital clinical assessments to remote cloud-based delivery for decentralised trials without compromising validity.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
Wearable-derived digital biomarkers have been accepted by regulatory agencies as endpoints in clinical trials for Duchenne muscular dystrophy, showing their potential to support decentralised diagnostics through patient-centric monitoring. This matters because it enables more sensitive and continuous assessment of disease progression outside clinical settings.
This study validated a low-cost 3D-printed smartphone attachment and paper sensor for measuring glucose, uric acid and cholesterol in saliva, demonstrating high correlation with standard ELISA results in a small clinical cohort. The authors suggest this platform offers a scalable solution for decentralised diabetes management by balancing sensitivity with affordability.
A machine learning model called Remote Control was trained on 2685 blood samples to predict change due to instability, enabling accurate calibration of results to approximate the time zero value at collection. With calibration, unprocessed whole blood could be transported for up to 9 days under ambient conditions and temperatures between 3.4 and 47.4 degrees Celsius, achieving agreement with CLIA TEa between 98.1 and 100 per cent and expanding the catalog of tests available for at-home collection.
This developer study reports that a self-collection kit interfacing with a BD Microtainer produced RNA of sufficient quality and yield for transcriptomic analysis in a pilot group and a longitudinal rheumatology cohort. Most participants found the device easy to use, supporting its utility for decentralised blood sampling.
Low-volume blood collection devices enable frequent, longitudinal sampling at home with reduced invasiveness, thereby improving participant retention in patient-centric studies. This facilitates decentralised biomarker monitoring for tracking disease progression and understanding physiological responses to diet, medication and physical activity.